<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/54BE99BE-2718-429B-B851-CF6393F28E98"><gtr:id>54BE99BE-2718-429B-B851-CF6393F28E98</gtr:id><gtr:name>Xstalbio Ltd.</gtr:name><gtr:address><gtr:line1>CIDS, THOMSON BUILDING , UNIVERSITY AVENUE</gtr:line1><gtr:city>GLASGOW</gtr:city><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/54BE99BE-2718-429B-B851-CF6393F28E98" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>54BE99BE-2718-429B-B851-CF6393F28E98</gtr:id><gtr:name>Xstalbio Ltd.</gtr:name><gtr:address><gtr:line1>CIDS, THOMSON BUILDING , UNIVERSITY AVENUE</gtr:line1><gtr:city>GLASGOW</gtr:city><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>74812.0</gtr:offerGrant><gtr:projectCost>99762.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FB558F5F-BB21-4773-9C7A-65E79D35B239"><gtr:id>FB558F5F-BB21-4773-9C7A-65E79D35B239</gtr:id><gtr:firstName>Marie-Claire</gtr:firstName><gtr:surname>PARKER</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=131455"><gtr:id>BA920AF6-B89E-49B8-BC00-721816E50493</gtr:id><gtr:title>RADICAL FORMULATIONS FOR SUSTAINED DELIVERY OF SMALL PROTEIN THERAPEUTICS</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Feasibility Studies</gtr:grantCategory><gtr:grantReference>131455</gtr:grantReference><gtr:abstractText>Many biopharmaceutical companies are developing new smaller biologic drug formulations with the aim of superceding the current generation of expensive monoclonal antibodies with medicines that are better targeted, more potent and cheaper to manufacture. A major drawback of such small biologic drugs is that following administration, usually by injection, they are typically cleared by the body in only a few hours. In this project, XstalBio will test a new method of trapping biologic drugs within injectable particles that are designed to slowly release the drug into the bloodstream. These particles contain only ingredients naturally present in the body and if they work as predicted would mean that patients would need an injection of drug only once a week instead of twice daily.</gtr:abstractText><gtr:fund><gtr:end>2014-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2013-11-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>74812</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">131455</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>